Literature DB >> 10919505

Respiratory infections and asthma.

E Micillo1, A Bianco, D D'Auria, G Mazzarella, G F Abbate.   

Abstract

Clinical and experimental evidence suggests an important role for respiratory infections in the development of asthma attacks. Viral upper respiratory infections have been associated with 80% of asthma exacerbations in children and 50% of all asthma episodes in adults. Human rhinovirus has been implicated as the principal virus associated with asthma episodes. Separate studies indicate that atypical bacteria such as Chlamydia pneumoniae and Mycoplasma pneumoniae may precipitate asthma symptoms. Although not completely clarified, the intricate pathogenetic mechanisms by which viral infections promote asthma attacks have been extensively investigated in recent years. By contrast, it has not yet been established whether atypical bacterial infections are an epiphenomenon or a pathogenic event in asthma.

Entities:  

Mesh:

Year:  2000        PMID: 10919505     DOI: 10.1034/j.1398-9995.2000.00506.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  17 in total

1.  NOD-like receptors and RIG-I-like receptors in human eosinophils: activation by NOD1 and NOD2 agonists.

Authors:  Anne Månsson Kvarnhammar; Terese Petterson; Lars-Olaf Cardell
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

2.  Human rhinovirus recognition in non-immune cells is mediated by Toll-like receptors and MDA-5, which trigger a synergetic pro-inflammatory immune response.

Authors:  Kathy Triantafilou; Emmanouil Vakakis; Edward A J Richer; Gareth L Evans; Joseph P Villiers; Martha Triantafilou
Journal:  Virulence       Date:  2011-01-01       Impact factor: 5.882

3.  Increase in granzyme B+ lymphocytes and soluble granzyme B in bronchoalveolar lavage of allergen challenged patients with atopic asthma.

Authors:  K Bratke; B Böttcher; K Leeder; S Schmidt; M Küpper; J C Virchow; W Luttmann
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

4.  Host modulators of H1N1 cytopathogenicity.

Authors:  Samuel E Ward; Hyun Seok Kim; Kakajan Komurov; Saurabh Mendiratta; Pei-Ling Tsai; Mirco Schmolke; Neal Satterly; Balaji Manicassamy; Christian V Forst; Michael G Roth; Adolfo García-Sastre; Katarzyna M Blazewska; Charles E McKenna; Beatriz M Fontoura; Michael A White
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

Review 5.  Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria.

Authors:  Judith Miklossy
Journal:  J Neuroinflammation       Date:  2011-08-04       Impact factor: 8.322

6.  Diminished levels of nasal S100A7 (psoriasin) in seasonal allergic rhinitis: an effect mediated by Th2 cytokines.

Authors:  Anne Månsson Kvarnhammar; Camilla Rydberg; Malin Järnkrants; Mia Eriksson; Rolf Uddman; Mikael Benson; Lars-Olaf Cardell
Journal:  Respir Res       Date:  2012-01-09

7.  Intranasal administration of poly(I:C) and LPS in BALB/c mice induces airway hyperresponsiveness and inflammation via different pathways.

Authors:  Magnus Starkhammar; Susanna Kumlien Georén; Linda Swedin; Sven-Erik Dahlén; Mikael Adner; Lars Olaf Cardell
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

Review 8.  Common mechanisms involved in Alzheimer's disease and type 2 diabetes: a key role of chronic bacterial infection and inflammation.

Authors:  Judith Miklossy; Patrick L McGeer
Journal:  Aging (Albany NY)       Date:  2016-04       Impact factor: 5.682

9.  Asthma prevalence and risk factors among children and adolescents living around an industrial area: a cross-sectional study.

Authors:  Giancarlo Ripabelli; Manuela Tamburro; Michela Lucia Sammarco; Guglielmo de Laurentiis; Andrea Bianco
Journal:  BMC Public Health       Date:  2013-11-04       Impact factor: 3.295

10.  Toll-like receptor ligands LPS and poly (I:C) exacerbate airway hyperresponsiveness in a model of airway allergy in mice, independently of inflammation.

Authors:  Magnus Starkhammar; Olivia Larsson; Susanna Kumlien Georén; Marina Leino; Sven-Erik Dahlén; Mikael Adner; Lars-Olaf Cardell
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.